|
Showing 1 - 2 of
2 matches in All Departments
In this work, an international panel of RNAi experts critically
reviews the most interesting advances in basic applied RNAi
research, highlighting the applications in RNAi-based therapies and
discussing the technical hurdles that remain.
This book centers on gene therapy and gene transfer approaches to
prevent or treat chronic virus infections. The main focus is on the
Big Three: human immunodeficiency virus (HIV-1), hepatitis B virus
(HBV) and hepatitis C virus (HCV). Ample anti-HIV drugs are
currently available in the clinic and the development of an
effective combination therapy has dramatically improved the
lifespan and quality of life of infected individuals. A similar
trend can already be recognized for HBV and HCV: the development of
multiple (directly acting) antiviral drugs and plans to control or
even cure the infection. However, approaches that help prevent
infection, or which provide long-lasting treatment (such as a cure)
remain important goals. Immunization through gene transfer vehicles
encoding immunogenic viral proteins shows promise in preventing
infections with complex, highly variable, viruses such as HIV-1 or
HCV. Gene therapy applications for virus infections have been
discussed since the early 1990's. Whereas a true cure seems
difficult to achieve for HIV-1 due to its intrinsic property to
deposit its genome into that of the host, such attempts may be
within reach for HCV where spontaneous viral clearance occurs in a
small percentage of the infected individuals. The prospect of
original gene therapy approaches may provide alternative ways to
reach the same endpoint by, for example, silencing of CCR5
expression post-transcriptionally. Many alternative antiviral
strategies have been developed based on a variety of novel
molecular methods: e.g. ribozymes. Some studies have progressed
towards pre-clinical animal models and a few antiviral gene
therapies have progressed towards clinical trials. This book
provides an overview of this rapidly progressing field, while
focusing on the interface of gene therapy and
immunology/vaccinology.
|
|